Appendicular lean mass is lower in late compared with early perimenopausal women: potential role of FSH
- 1 May 2020
- journal article
- research article
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 128 (5), 1373-1380
- https://doi.org/10.1152/japplphysiol.00315.2019
Abstract
Age-related declines in skeletal muscle mass (i.e., sarcopenia) contribute to physical disability in older women. Although a menopause-related increase in fat mass is well documented, whether menopause influences muscle mass and sarcopenia is unclear. We determined the extent to which skeletal muscle mass differs across the stages of the menopause transition in women and whether these differences are associated with estradiol or other sex hormones. This was a cross-sectional study of 144 healthy women (aged 30–70 yr) classified as premenopausal [n = 30, 38 ± 6 yr (means ± SD)], early (n = 31, 50 ± 3 yr) and late (n = 30, 50 ± 4 yr) perimenopausal, and early (n = 26, 55 ± 3 yr) and late (n = 27, 62 ± 4 yr) postmenopausal. Appendicular lean mass (ALM) adjusted by the square of height in meters (ALM index; ALMi) was assessed by dual-energy X-ray absorptiometry. ALMi was lower (P < 0.05) in late perimenopausal and postmenopausal compared with early perimenopausal, with no significant differences between other groups (premenopausal 6.6 ± 0.6, early perimenopausal 6.8 ± 0.8, late perimenopausal 6.1 ± 0.8, early postmenopausal 6.5 ± 1.1, and late postmenopausal 6.2 ± 0.9 kg/m2). The prevalence of sarcopenia (ALMi ≤ 5.67 kg/m2) was 7%, 3%, 30%, 27%, and 32% in premenopausal, early and late perimenopausal, and early and late postmenopausal groups, respectively. ALMi measured across menopause stages was inversely correlated to follicle-stimulating hormone (FSH; r = −0.28, P = 0.003) but not to estradiol (r = 0.088, P = 0.34). The menopause transition appears to be a vulnerable period for the loss of skeletal muscle mass that may begin during the late perimenopausal transition. Future studies are necessary to investigate the potential effect of FSH on skeletal muscle. NEW & NOTEWORTHY Our data suggest that the late perimenopausal stage may be a vulnerable period for the loss of skeletal muscle, potentially related to elevations in FSH.Keywords
Funding Information
- HHS | NIH | National Institute on Aging (R01 AG027678, R01 AG049762)
- HHS | NIH | National Institute on Aging (R01 AG053489)
- HHS | NIH | National Heart, Lung, and Blood Institute (R56 HL114073)
- HHS | NIH | National Institute of Child Health and Human Development (P50 HD073063)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK048520)
- HHS | NIH | National Center for Advancing Translational Sciences (UL1 TR001082)
- U.S. Department of Veterans Affairs (Eastern Colorado VA GRECC)
This publication has 47 references indexed in Scilit:
- Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesisProceedings of the National Academy of Sciences of the United States of America, 2012
- Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on SarcopeniaJournal of the American Medical Directors Association, 2011
- Chronic Medical Conditions and the Sex-based Disparity in Disability: The Cardiovascular Health StudyThe Journals of Gerontology: Series A, 2010
- Timing of ibuprofen use and bone mineral density adaptations to exercise trainingJournal of Bone and Mineral Research, 2010
- Hormone Therapy and Skeletal Muscle Strength: A Meta-AnalysisThe Journals of Gerontology: Series A, 2009
- Increases in Bone Mineral Density in Response to Oral Dehydroepiandrosterone Replacement in Older Adults Appear to Be Mediated by Serum EstrogensJournal of Clinical Endocrinology & Metabolism, 2008
- Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal womenMenopause, 2006
- Effects of 20-mg oestradiol implant therapy on bone mineral density, fat distribution and muscle mass in postmenopausal womenActa Diabetologica, 2003
- Body fat distribution and body composition during GnRH agonist therapyObstetrics & Gynecology, 2001
- Hemostatic, Metabolic, and Androgenic Risk Factors for Coronary Heart Disease in Physically Active and Less Active Postmenopausal WomenArteriosclerosis, Thrombosis, and Vascular Biology, 1995